S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 102-103
10.1097/01.hs9.0000843696.37630.1c